Problems in the classification of CMML--dysplastic versus proliferative type

Area of Science:

• Hematology
• Oncology
• Clinical Pathology

Background:

• The French-American-British (FAB) classification proposed two subgroups for chronic myelomonocytic leukemia (CMML): myelodysplastic (MDS-CMML) and myeloproliferative (MPD-CMML), based on leukocyte count.
• Distinguishing these CMML subtypes is crucial for understanding disease heterogeneity and potential prognostic implications.

Purpose of the Study:

• To compare the clinical and hematological features of MDS-CMML and MPD-CMML.
• To evaluate the prognostic significance of the FAB classification in CMML patients.

Main Methods:

• Retrospective analysis of 158 CMML patients.
• Comparison of clinical presentation, laboratory findings, and survival rates between MDS-CMML and MPD-CMML groups.
• Assessment of transformation to acute myeloid leukemia (AML) and application of scoring systems (Düsseldorf-score).

Main Results:

• No significant difference in median age at diagnosis between the two groups.
• MPD-CMML showed a higher prevalence of splenomegaly, elevated LDH, and serum deoxythymidine kinase levels.
• Survival rates and probability of AML transformation did not significantly differ between MDS-CMML and MPD-CMML, though MDS-CMML showed a trend towards higher AML transformation.
• The Düsseldorf-score identified distinct risk groups within MDS-CMML, but not within MPD-CMML.

Conclusions:

• MDS-CMML and MPD-CMML represent clinically distinct entities but offer limited prognostic information based on the FAB classification alone.
• Further research is needed to determine if therapeutic responses differ between these CMML subtypes.
• The Düsseldorf-score is useful for risk stratification within the MDS-CMML subgroup.